Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03019536 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03019536 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 22 participants.
The verdict
NCT03019536, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is handled by the body and acts in the body. This study will last up to 65 weeks, not including screening. Screening is required within 90 days prior to the start of the study.
Interventions
- DRUG Flortaucipir F18
- DRUG Florbetapir F 18
- DRUG Placebo - IV
- DRUG LY3303560 - IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2019-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03019536
The ClinicalTrials.gov registry entry for NCT03019536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Flortaucipir F18 is the first listed.
NCT03019536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03019536 about?
NCT03019536 is a clinical study titled "A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease". The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is handled by the body and acts in ...
What is the current status of trial NCT03019536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-01-31. Estimated completion is 2019-06-05.
What interventions are being tested in trial NCT03019536?
The interventions under investigation include: Flortaucipir F18 (DRUG), Florbetapir F 18 (DRUG), Placebo - IV (DRUG), LY3303560 - IV (DRUG).
Who is sponsoring clinical trial NCT03019536?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.